Does NIVOLUMAB Cause Immune-mediated myocarditis? 444 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 444 reports of Immune-mediated myocarditis have been filed in association with NIVOLUMAB (OPDIVO). This represents 0.5% of all adverse event reports for NIVOLUMAB.
444
Reports of Immune-mediated myocarditis with NIVOLUMAB
0.5%
of all NIVOLUMAB reports
122
Deaths
294
Hospitalizations
How Dangerous Is Immune-mediated myocarditis From NIVOLUMAB?
Of the 444 reports, 122 (27.5%) resulted in death, 294 (66.2%) required hospitalization, and 163 (36.7%) were considered life-threatening.
Is Immune-mediated myocarditis Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for NIVOLUMAB. However, 444 reports have been filed with the FAERS database.
What Other Side Effects Does NIVOLUMAB Cause?
Death (11,216)
Malignant neoplasm progression (9,363)
Off label use (5,208)
Diarrhoea (4,692)
Fatigue (3,709)
Pyrexia (3,454)
Intentional product use issue (3,297)
Rash (2,816)
Nausea (2,805)
Decreased appetite (2,619)
What Other Drugs Cause Immune-mediated myocarditis?
PEMBROLIZUMAB (599)
IPILIMUMAB (248)
CARBOPLATIN (93)
DURVALUMAB (74)
LENVATINIB (66)
DOXORUBICIN (59)
PACLITAXEL (58)
PEMETREXED (43)
ATEZOLIZUMAB (37)
BEVACIZUMAB (32)
Which NIVOLUMAB Alternatives Have Lower Immune-mediated myocarditis Risk?
NIVOLUMAB vs NIVOLUMAB\RELATLIMAB-RMBW
NIVOLUMAB vs NIZATIDINE
NIVOLUMAB vs NOMEGESTROL
NIVOLUMAB vs NORDAZEPAM
NIVOLUMAB vs NOREPINEPHRINE